Topics

Cellular Bio Starts China Trial of Stem Cell Treatment for Arthritic Knees

04:19 EDT 13 Sep 2019 | ChinaBio Today

Cellular Biomedicine, launched a China Phase II trial for AlloJoin®, its stem cell treatment for knee osteoarthritis (KOA). The trial is the first stem cell trial approved by the NMPA since it revamped China's cell therapy regulations in late 2017. AlloJoin is an off-the-shelf product comprised of allogenic human adipose-derived mesenchymal progenitor cells. The NMPA has also accepted for review CMBG's IND application to conduct a Phase II trial for ReJoin®, its autologous haMPC therapy, also aimed at KOA. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:

Original Article: Cellular Bio Starts China Trial of Stem Cell Treatment for Arthritic Knees

NEXT ARTICLE

More From BioPortfolio on "Cellular Bio Starts China Trial of Stem Cell Treatment for Arthritic Knees"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Joint Disorders
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...